PLIANT THERAPEUTICS I

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis

22 Jan 2023 13:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

15 Dec 2022 07:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

15 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

08 Nov 2022 15:02:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium

05 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors

15 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

01 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

30 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

08 Aug 2022 15:05:02 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in BTIG Biotechnology Conference

02 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis

21 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

15 Jul 2022 15:03:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering

12 Jul 2022 18:46:28 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Proposed Public Offering of Common Stock

11 Jul 2022 15:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

10 Jul 2022 17:10:21 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial

24 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

22 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

16 Jun 2022 07:00:02 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022

15 Jun 2022 15:01:00 By Nasdaq GlobeNewswire